NEW YORK, Dec 29 – Paradigm genetics has licensed the Rosetta Resolver gene expression analysis system from Rosetta Inpharmatics and Agilent Technologies, the companies announced Friday.

The companies did not disclose the financial terms of the agreement. Agilent has been the exclusive distributor of the Rosetta Resolver, a bioinformatics gene expression analysis system that can be used with a variety of microarrays, since December 1999.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.